ACELYRIN
Manufacturing · California, United States · 135 Employees
View Company Info for Free
About
Headquarters
4149 Liberty Canyon Rd, Agoura Hills, Californi...Phone Number
(805) 730-0360Website
www.acelyrin.comRevenue
$375.3 MillionStock Symbol
SLRNIndustry
Most Recent Scoops
Highlights
$1.1B
Total Funding Amount
$540M
Most Recent Funding Amount
4
Number of Funding Rounds
Who is ACELYRIN
ACELYRIN Org Chart
Is ACELYRIN your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
ACELYRIN, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ACELYRIN is spiking on competitors!
Funding: Get notified immidiatlly once ACELYRIN has new funding data
Earning: See what the market has to say on ACELYRIN recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ACELYRIN launches new products
Click to see if ACELYRIN had a recent Job posting/layoffs
Check if ACELYRIN has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ACELYRIN
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at ACELYRIN
Find 3 more new buyers
Compare Similar Companies to ACELYRIN
Compare insights from companies similar to ACELYRIN, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
ACELYRIN
ACELYRIN financials insights
Gather financial insights about ACELYRIN, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
ACELYRIN Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
ACELYRIN Tech Stack
A closer look at the technologies used by ACELYRIN
Most Recent Scoops
ACELYRIN News & Media
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event willACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significanceACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding ACELYRIN
ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. The company was founded in 2020 and is headquartered in Agoura... Read More